Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
WALTHAM, Mass., April 01, 2016 -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on March 28, 2016, the compensation committee of the company's board of directors granted sixteen new non-executive employees options to purchase an aggregate of 171,600 shares of the company's common stock with a per share exercise price of $30.25, the closing trading price of the company’s common stock on the NASDAQ Global Market on the grant date. Each option vests 25% on the first anniversary of the employee’s hire date, with the remaining 75% to vest in monthly installments over the three years thereafter, and has a ten-year term. The stock options were granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules for equity grants to induce the new employees to enter into employment with the company.
About Radius Health
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer. For more information, please visit www.radiuspharm.com.
Radius Health Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825 Media Contact: Lori Gorski Email: [email protected] Phone: 617-551-4096
